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“My heart and kidneys are fighting each other; 
Call a truce to this civil war.” 
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Professor Paul Brink introduced me to a "stepchild" in Cardiology: the autonomic nervous 
system and its central role in malignant cardiac arrhythmias. Our mentoring relationship and 
friendship started more than two decades ago. He taught me about sudden cardiac death the 
long QT syndrome and hypertrophic cardiomyopathy and connected me with world-famous 
researchers of whom Professor Peter Schwartz played a central role in developing our current 
thinking about autonomic nervous system modulation of cardiac arrhythmias. 
 
I became an interventional cardiologist but remained interested in the autonomic nervous 
system and its effect on sudden cardiac death and atrial fibrillation. Renal denervation (RD) 
was introduced as a novel, minimally-invasive blood pressure-lowering procedure. In 2012, I 
approached the device company, Medtronic, with my idea that RD could potentially be used 
as an anti-fibrillatory tool, and after many refusal letters, they finally accepted my research 
proposal! 
 
Trouble on the horizon 
I was never interested in blood pressure lowering from a research perspective, especially after 
the disappointing results of SYMPLICITY HTN-3. This trial is considered a landmark trial which 
emphasized the power of a “sham” procedure. Although SYMPLICITY HTN-3 had technical 
limitations, it lead to the design of new catheters and three ongoing trials that demonstrated 
a modest reduction in blood pressure between 5-10mmHg. Nonetheless this was far less than 
the previous reports in unblinded controls without a sham procedure of a 30-mm drop in 






Many concerned colleagues warned me that I was on a sinking ship and that I should consider 
changing my PhD. Paul Brink and my wife, Tania Heradien, encouraged me during the stormy 
seas that followed. Despite these challenges, I continued dreaming about the anti-arrhythmic 
effects of RD.  
 
A silver lining behind the dark cloud? 
The results of my study were quite surprising, unexpected (e.g. reduction in NSTEMI 
incidence) and sometimes, even disappointing. I console myself that other researchers will 
continue to challenge dogma and push scientific boundaries until they break! In this regard, I 
dedicate this work to the late Professor Bongani Mayosi, who was such a researcher.  
 
 
My heartfelt thanks to you for all your input and encouragement! Thank you also to the 
Hamilton Naki Trust for providing me with financial study support. Let us continue to live our 
lives by the Ubuntu principle and share knowledge freely to empower Africa and equip her 
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Atrial fibrillation (AF) is associated with increased cardiovascular morbidity and mortality, but it is uncertain 
if catheter-based renal denervation (RD) can reduce AF in patients with hypertensive heart disease (HHD). 
METHODS 
Patients who were ≥ 55 years old, in sinus rhythm, taking ≥ 3 anti-hypertensive drugs including a diuretic, 
with echocardiogram-confirmed HHD and suspected coronary artery disease, were randomised to undergo 
RD or sham procedure. Patients with renal impairment, significant valvular heart disease and untreated 
thyroid disease were excluded. The primary endpoint, the first episode of subclinical AF (SAF) lasting ≥ 6 
minutes, was detected using an implantable loop recorder which was scanned every six months. Six-month 
follow-up (6MFU) office systolic blood pressure (SBP), cardiovascular mortality and restoration of 
autonomic imbalance were secondary endpoints.  
RESULTS 
Eighty patients were randomised: 42 underwent RD and 38 a sham procedure. After an average follow-up 
of three years, fewer RD patients experienced SAF: 6 of 42 patients (14.3%) vs 15 of 38 (39.5%) sham 
patients (odds ratio (OR), 0.26; 95% CI, 0.1 to 0.71, p = 0.01). Fast AF (ventricular rate ≥ 100 bpm) occurred 
in 10 sham patients (26.3%) vs 1 RD patient (2.4%): OR, 14.64; 95% CI, 1.77 to 120.91; p = 0.002). The 
incidence of cardiovascular death was higher in the sham than RD group (6 of 38 (15.8%) vs 1 of 42 (2.4%): 
OR, 7.69; 95% CI, 0.88 to 67.12; p = 0.049). Non-ST elevation myocardial infarction (NSTEMI) incidence was 
lower in the RD than sham group (2.3% vs 18.4%: OR, 0.108; 95% CI, 0.01–0.92; p = 0.02). The 6MFU 
between-group SBP difference was not significant (−3.8 mmHg; p = 0.49). Resting and one-minute recovery 
heart rate did not differ between groups at 6MFU. 
CONCLUSION 
In patients with HHD, RD reduces subclinical and fast AF, NSTEMI and cardiovascular death independent of 








This section focuses on the epidemiology and current treatment guidelines of hypertension. 
Non-adherence to oral anti-hypertensive drugs (AHD) limit their efficacy and should be 
excluded in every patient with so-called “resistant hypertension”. Different AHD classes are 
discussed, focusing on sympathetic nervous system overactivity and its association with 
hypertensive heart disease (HHD) and paroxysmal atrial fibrillation (AF). Current AF 
management and its shortcomings, as well as the rationale why catheter-based renal 
denervation may be considered as alternative upstream therapy to prevent AF in patients 
with HHD are also discussed. 
 
Hypertension epidemiology and target organ damage 
Hypertension (HT) remains the most common and modifiable cardiovascular risk factor. In 
2015, the global prevalence of HT, based on an office blood pressure of > 140/90 mmHg was 
estimated to be 1.13 billion.1 Although the prevalence of HT is declining in high-income 
countries, an increased prevalence has been reported in lower-income Sub-Saharan and East-
European countries.2 Current data also indicate that the incidence of newly-diagnosed 
hypertension is increasing among young adults and both genders.3 More than 60% of people 
aged > 60 years have hypertension.4 South Africa has probably one of the highest prevalences 
of HT (77.9%) among older adults within low and middle-income countries.5 Uncontrolled HT 
is associated with damage to target organs including the brain, eyes, heart and kidneys. 
Cardiac complications of uncontrolled HT include hypertensive heart disease (HH), coronary 





Current ESC/ESH guidelines for the treatment of hypertension 
Current treatment guidelines recommend lifestyle changes as the first step in the 
management of arterial HT.7 These include dietary adaptations such as salt reduction and 
increased fruit and vegetable intake. Increased physical activity, at least 30 minutes/day for 
most days of the week, also lowers blood pressure. Although these lifestyle changes can 
induce significant blood pressure lowering, they are often hard to maintain. A randomised 
controlled trial showed that motivated patients can maintain the blood pressure-lowering 
effect for up to 18 months, which could help to delay starting with anti-hypertensive 
treatment and of diabetes mellitus.8 Frequently, however, most patients will need life-long 
drug therapy to reduce the risk associated with uncontrolled HT.  
 
Non-adherence to anti-hypertensive therapies is the most common cause of uncontrolled HT. 
It is estimated that 50% of hypertensive patients will become non-adherent to their 
prescribed medicines within the first year of diagnosis.9 One of major explanations for 
nonadherence to antihypertensive therapies is that patients are simply not compliant and not 
necessarily because of side effects but because they are not sufficiently symptomatic with 
hypertension until they get complications.   
 
Several anti-hypertensive drug classes may be used, but 2018 ESC guidelines recommend that 
most patients should be treated with a single-pill strategy that contains at least two anti-
hypertensive drugs of different classes.7 Any combination is physiologically feasible, but 
angiotensin-converting enzyme (ACE) inhibitors should preferably not be combined with 
angiotensin receptor blockers because of the risk of irreversible renal failure, hyperkalaemia 




Types of anti-hypertensive drugs and their side effects 
Diuretics are most commonly prescribed and are usually effective to lower blood pressure, 
but thiazide diuretic use is associated with hyperglycemia, hyperuricaemia, hypokalaemia and 
dyslipidaemia.11 Recently an association with skin cancers was reported with thiazide diuretic 
use.12 When compared to thiazide diuretics, thiazide-like agents, such as Indapamide, 
resulted in an additional 12% relative risk reduction (RRR) for cardiovascular events and a 21% 
additional RRR for heart failure.13 These agents are also “metabolically neutral”, implying that, 
unlike thiazides, they do not worsen the patient’s lipid or diabetes profile. Thiazides are 
cheaper than thiazide-like agents and remain the preferred diuretic in resource-poor settings.  
 
Renin-angiotensin system blockers are essentially vasodilators which are especially effective 
in non-African, hypertensive patients.14 Angiotensin converting enzyme inhibitors (ACE-I) 
significantly lower the production of angiotensin II and raise nitric oxide levels via increased 
bradykinin levels.15 This beneficial effect of ACE-inhibitors is sometimes associated with an 
intractable cough, which often leads to discontinuation of this valuable therapy. Angiotensin-
receptor blockers (ARBs) produce much less cough and accordingly, associate with much less 
drug discontinuation than ACE-inhibitors.16 In meta-analyses, however, ARB treatment could 
not demonstrate any cardiovascular mortality reduction (HR: 0.99, 95% CI: 0.94–1.04).17 ACE-
inhibitors on the other hand, reduced overall cardiovascular mortality by 10% (HR: 0.90, 95% 
CI: 0.84–0.97). Despite the statistically significant cardiovascular mortality benefit of ACE-I 
over ARBs, current ESC guidelines do not recommend one agent over the other. It is probably  
important here to mention that the ACEi trials were performed during an earlier time period 





Aldosterone antagonists prevent the reabsorption of sodium and water in the distal 
convoluted renal tubules. Spironolactone remains a valuable drug in the management of low-
renin states and resistant hypertension, but treatment is associated with hyperkalaemia and 
gynaecomastia, which is less common with eplerenone.18, 19 Amiloride is also a potassium-
sparing diuretic with mild natriuretic and diuretic properties.20 It selectively blocks sodium 
transport in the distal renal tubule which inhibits sodium-potassium exchange. 
Hyperkalaemia, nausea and vomiting, loss of appetite, muscle cramps and impotence are 
common side effects which may reduce adherence.  
 
Non-dihydropyridine calcium channel blockers are a mainstay of blood pressure lowering 
therapy in many parts of the world. Dihydropyridine calcium channel blockers are also 
effective in the management of hypertension, but treatment is associated with ankle oedema, 
which may lead to non-adherence. This class of anti-hypertensive treatment is preferred in 
black hypertensive patients, but should preferably be avoided in patients with heart failure 
with a reduced ejection fraction (HFrEF). 21 Hydralazine is a vasodilator that reduces 
peripheral resistance by working directly on vascular smooth muscle cells. Reflex tachycardia 
with angina, gastro-intestinal side effects and drug-induced systemic lupus erythematosus 
may limit its use.22  
 
Alpha-blockers (AB) are vasodilators and considered a valuable add-on anti-hypertensive 
therapy especially in males with benign prostate hyperplasia.23 Unfortunately, AB treatment 
is associated with orthostatic hypotension which may increase the risk of falls and fractures 
in the elderly. Beta blockers are second line agents in the treatment of hypertension probably 




impotence compared to other anti-hypertensive classes.24 In the ASCOT trial, Atenolol, which 
is still used in the South African state sector, increased the risk to develop diabetes mellitus.25  
Despite these negative associations, BB remain important drugs in the treatment of patients 
with long QT syndrome, ischemic heart disease and heart failure.26, 27 
 
Does sympathetic activity play a role in atrial f ibril lation? 
Several conditions are associated with increased sympathetic tone (IST) which plays a central 
role in the development of HHD. These include the metabolic syndrome (central obesity, 
hypertension, insulin resistance, dyslipidaemia and hypercoagulability), obstructive sleep 
apnoea, diabetes mellitus, emotional stress and depression.28-30 HHD is characterised by left 
ventricular hypertrophy (LVH), diastolic dysfunction, increased left atrial pressure (LAP) and 
left atrial dilatation.31 Increased LAP stretches the pulmonary veins and induces ectopic 




Figure 1. Increased sympathetic tone promotes the pathogenesis of non-valvular atrial 
fibrillation. Proposed mechanism of how increased sympathetic tone promotes the 
development of hypertensive heart disease, left atrial dilatation and stretching of the 
pulmonary veins. Adrenergic surges can precipitate subclinical and fast AF on this primed 




This situation may change, however, when the patient experiences a sudden surges of 
increased sympathetic tone which releases catecholamines on the primed substrate, the 
pulmonary venous ostia. Typical triggers of these events are hypoglycaemia, hypoxia and 
acute myocardial ischemia. Hypoglycaemia may be a side effect of administered insulin or 
first-generation sulfonylurea drugs. In the DEVOTE 3 trial, patients who experienced insulin-
induced severe hypoglycaemia were at greater risk of death after the hypoglycaemic 
episode.32 Hypoxia may be experienced by patients with obstructive sleep apnoea (OSA) and 
myocardial ischemia, which may be either acute or chronic, occur in patients with obstructive 
coronary artery disease. During these hyper-adrenergic events, short duration and fast AF 
occurs.33 These short-lived episodes seldom cause symptoms, unless the patient has advanced 
left ventricular diastolic dysfunction. The association between symptomatic atrial fibrillation, 
obesity, and OSA appears to be strong: in anyone with nocturnal development of atrial 
fibrillation it should be considered and in patients undergoing radio-frequency ablation, 
screening for OSA is advisable.34 It is also important to remember that the same risk factors 
which increase sympathetic tone can also increase arterial stiffness which in turn causes 
diastolic dysfunction and increased left atrial volume.35 Furthermore, a large atrium is 
electrically unstable due to inhomogeneity in conduction and refractoriness.36 
 
Atrial fibril lation: epidemiology, predisposing factors and pathogenesis 
AF is the most prevalent sustained cardiac arrhythmia. Millions of people are affected 
worldwide and the prevalence increases with age.37 Males are more frequently affected than 
females.37 It is estimated that in the next decade, 14–17 million people in the European Union 
will be diagnosed with AF.39 Non-valvular AF occurs more frequently in developed countries, 




quicker diagnosis and associates with increased life expectancy. It is also well documented 
that there is a lower incident AF  rate amongst black Americans and perhaps other black 
populations even though they have more left ventricular hypertrophy.40   
 
This picture may be different in developing countries, however. An Ethiopian community-
based, cross-sectional study recently reported a relatively high prevalence of AF of 4.3% in 
634 adults screened with a 12 lead ECG, but AF prevalence data in Sub-Saharan Africa remain 
sparse, despite the relatively high prevalence of valvular heart disease.41, 42 Conditions that 
are independently associated with AF include diabetes mellitus, obesity, ischemic heart 




Figure 2. Hazard ratios of risk factors that are independently associated with non-valvular 
Atrial Fibrillation. Adapted from 2016 ESC guidelines on Atrial Fibrillation: 
www.escardio.org/guidelines.43 




Young people (age < 60 years) with a normal BMI and no other cardiovascular risk factors do 
not have an increased risk to develop AF. Lone AF, also referred to as “vagal AF”, which may 
be genetically determined to some extent, occurs more frequently in younger than older 
patients. Octogenarians have the highest risk to develop AF (HR: 9.33; 95% CI: 6.68–13.0) and 
in patients with hypertension the risk to develop AF is increased by 32% compared to 
normotensive controls. In patients with the metabolic syndrome, AF risk may increase 
exponentially due to the combination of risk factors, including obesity, hypertension, diabetes 
mellitus and myocardial ischemia. Although AF can occur in structurally normal hearts, left 
atrial dilatation remains an important contributor for AF pathogenesis and embolic stroke 
risk.44 The left atrium undergoes several morphological and electrical changes after the first 
AF episode.45 These changes are mediated by IST (Figure 3).  
 
Figure 3. Pathogenesis of AF. Increased sympathetic tone links many of the components that 






Cytosolic calcium levels increase because of raised cAMP levels, driven by increased 
adrenergic stimulation of beta-1 receptors. This phenomenon, also referred to as “calcium 
signalling silencing”, promotes electrical instability and electrical re-entry mechanisms.46 IST 
also stimulates fibroblasts via aldosterone and purinergic signalling to produce interstitial 
collagen.47, 48 Stretch-induced atrial fibrosis follows, which fractionates the depolarising 
electrical wave front. IST is also associated with increased inflammation, which may damage 
endocardial cells and expose the sub-endocardium.49 Hypercoagulability, also mediated by 
IST, promotes left atrial appendage thrombosis and embolization to vital organs.50 
 
AF subtypes and proposed management 
The duration of AF is strongly associated with stroke risk.51 Paroxysmal AF, which often self-
terminates within seven days of onset, is a common complication of uncontrolled 
hypertension and HHD. This arrhythmia usually originates from the muscular sleeves inside 
the pulmonary veins where they enter the left atrium.52 AF becomes “persistent” if it lasts 
more than seven days. “Long-standing persistent” AF has to be present for at least one year 
in a patient who agrees to rhythm control of his arrhythmia. 
 
The rhythm control strategy of paroxysmal AF is controversial and can be accomplished by 
using either drugs or pulmonary venous isolation (PVI). Drug treatment with amiodarone, 
which is often life-long, is associated with dangerous side effects including thyroid 
dysfunction, corneal deposits, hepatic enzyme abnormalities and irreversible lung fibrosis. 
PVI, on the other hand, is performed under general anaesthesia with either “hot” or “cold” 
ablation in an attempt to electrically isolate the pulmonary veins from the left atrium. “Hot” 




venous ostia. “Cold” ablation uses liquid nitrogen to freeze the pulmonary venous-atrial 
junctions. The FIRE and ICE trial confirmed that cold ablation is as effective as hot ablation.53 
Radiofrequency ablation results in an improvement in the quality of life but even in the best 
hands, the  rate of a second ablation over five years is about 50% and the recurrence rate in 
patients with persistent or chronic AF and underlying LV dysfunction is even higher. Despite 
these technological advances, the rates of major and minor complications are about 3% each 
although phrenic nerve palsy and most often fatal ALA-esophageal fistula are rare.54 Even in 
patients undergoing pulmonary vein isolation/ablation if the CHADS-VASC score is 2 or more 
the current recommendation is that they remain on lifelong anticoagulation.43 
 
The rate control strategy aims to reduce the ventricular rate by slowing atrio-ventricular (AV) 
conduction and can be accomplished with either AV blocking agents, e.g. beta-blockers or 
non-dihydropyridine calcium channel blockers. In difficult cases, AV-nodal ablation and 
permanent pacing can also be used as an alternative. This last-resort treatment is not ideal, 
because permanent single chamber pacing promotes dyssynchronous ventricular 
contraction, which may reduce cardiac output and trigger a pacing-induced cardiomyopathy. 
AV-nodal ablation with His-bundle pacing or biventricular pacing may be more suitable to 
preserve ventricular synchrony, but no randomised trial has been performed to date to test 
this hypothesis.55 The patient with “permanent AF” agrees with his/her treating physician 
that a rate control strategy will be pursued. Lifelong oral anti-coagulation with warfarin or 
novel oral anticoagulants should be considered in all patients with a CHA2DS2-VASc score of 
≥2, unless contraindicated. Patients with contraindications to oral anti-coagulants, e.g. an 





Is upstream prevention of AF a possible “Holy Grail”? 
Despite major advances in diagnosis and treatment, the current management of AF remains 
associated with increased morbidity and mortality. Upstream prevention of AF may therefore 
be a desirable treatment option for patients who have an increased risk of developing AF. It 
is interesting to note that lifestyle modifications have been shown to reduce incident AF.57 
Weight loss and increased physical activity can also restore cardiovascular autonomic 
function.58, 59 The challenge with these recommendations is that they are very difficult to 
maintain, especially in the elderly. Modulating cardio-autonomic tone through device therapy 
remains an unexplored territory.  
 
RATIONALE 
Uncontrolled HT and HHD are the most frequent conditions that increase the risk to develop 
AF. The autonomic nervous system plays a central and mediating role in the pathogenesis and 
maintenance of non-valvular AF and as such, correcting autonomic imbalance may 
theoretically prevent AF in patients with HHD. 
 
What is autonomic imbalance? 
The autonomic nervous system consists of a sympathetic and parasympathetic system. 
During normal resting conditions, the parasympathetic system regulates the function of 
internal organs. The sympathetic system, which is also referred to as the “fight or flight 
system”, becomes activated when the brain senses impending danger that threatens survival. 
Sympathetic activation normally does not last long, but failure to switch off this system can 
result in autonomic imbalance (AI). AI defines a state of relative IST and/or decreased 




failure, atrial fibrillation, obesity and chronic kidney disease.60-63 Our modern lifestyle of high 
stress levels, reduced exercise and diets rich in salt and carbohydrates undoubtedly fuels both 
the metabolic syndrome and AI.  
 
AI and sudden cardiac death 
Interestingly, AI is also associated with sudden cardiac death (SCD) during severe emotional 
stress.64 Congenital long QT syndrome (LQTS) illustrates this association particularly well.65 
Symptomatic KCNQ1 mutation carriers with type 1 LQTS typically experience syncope, and 
sometimes SCD, during situations associated with IST, e.g. excitement, swimming or exercise. 
Conversely, higher resting vagal tone, seems to be protective and anti-sympathetic therapy, 
e.g. BB or left cardiac sympathetic denervation (LCSD), are now established therapies for 
type1 LQTS.66 Another example where AI associated with and even predicted SCD came from 
a prospective cohort of apparently healthy young French male civil servants. Here, Jouven et 
al. used exercise-related heart rate profiles as surrogate markers of cardio-autonomic tone.67 
They found that faster resting heart rate (> 75 bpm), indicative of IST and slower post-exercise 
recovery of heart rate (< 25 bpm), indicative of reduced parasympathetic tone, is associated 
with and predicted a significantly higher SCD risk later in life. These findings were recently 
confirmed using heart rate recovery at 10 seconds after cessation of exercise as a predictor 
of cardiovascular death in a prospective cohort of > 40 000 UK Biobank participants.68 Heart 
rate profiles during exercise and recovery can therefore be used as surrogate markers of 
cardio-autonomic tone and may also be inherited.69, 70 The heritability of these responses, 
which is really a reflection of the propensity of the heart and brain to behave in a certain way 





The heart, however, is not the only organ that feels the brunt of acute sympathetic activation: 
the kidneys are probably affected more chronically. They play an important regulating role 
which, in essence, augments overall sympathetic tone. The afferent renal nerves, mostly 
located in the renal pelvis, transmit signals via the dorsal spinal cord to the brain when 
activated by stretch forces (Figure 4).72 Activated centres in the brain include the nucleus 






These renal afferent nerve signals increase vasopressin and oxytocin release accompanied by 
increased activation of efferent sympathetic neurons. These efferent neurons run along 
paravertebral ganglia and large blood vessels, where they exit to vital organs located in the 
thoraco-lumbar region. In the thorax, sympathetic nerves terminate in the sino-atrial node, 
Figure 4. Renal nerves facilitate brain-kidney sympathetic cross talk and play a central role in the 
regulation of blood pressure and autonomic tone. SFO: subfornical organ; PVN: paraventricular 
nucleus of hypothalamus; RVLM: rostral ventrolateral medulla; NTS: nucleus tractus solitarius; IML: 




atrio-ventricular node and ventricles. Here, sympathetic stimulation increases chronotropy, 
dromotropy and inotropy, respectively. Cumulatively, these effects increase cardiac output 
and systolic blood pressure. The sympathetic nerves also pass through the stellate ganglia, 
which plays an important regulatory role in the propensity to develop tachyarrhythmias, e.g. 
ventricular tachycardia or atrial fibrillation.73  
 
In the lumbar region, the efferent sympathetic nerves enter the kidneys via the renal arteries. 
They arborise alongside the renal artery, run in the vasa vasorum and terminate in the 
efferent glomerular arteriole, the juxta-glomerular apparatus (JGA) and the renal tubules. JGA 
activation results in renin release, which activates the renin-angiotensin-aldosterone system 
(RAAS). The end products of RAAS activation, angiotensin II (AT-II) and aldosterone, induce 
vasoconstriction and renal tubular sodium and water retention, respectively. AT-II constricts 
the efferent glomerular arteriole, which raises intra-glomerular pressure and filtration rate. 
AT-II also increases peripheral resistance, which increases diastolic blood pressure, cardiac 
afterload and coronary perfusion, respectively.  
 
In the normal kidney, stretching of the renal pelvis inhibits the efferent sympathetic renal 
nerves. In the hypo-perfused kidney, however, the inhibitory reflex is attenuated and results 
in sympatho-exitation, increased cardiac output, augmented glomerular filtration and 
subsequent adrenal gland activation. Chronic and inappropriate activation of this system 
results in hypertension and its sequelae. Although IST is not the only cause of essential 
hypertension, there is strong evidence that the sympathetic nervous system plays a critical 





Modifying this system by cutting the nervous communication between the brain and the 
kidneys [renal denervation (RD)] may therefore not only improve renal perfusion, but also 
benefit the whole vascular tree and organ blood supply through pleiotropic effects. 
 
The kidneys play a central role in autonomic dysfunction 
The kidneys play a pivotal role in the pathogenesis of hypertension through autonomic 
regulation of increased peripheral resistance, sodium and water retention and other 
mechanisms.72 Anatomical and physiological knowledge of the renal nerve supply supports 
the hypothesis that RD lowers blood pressure and consequently produces beneficial cardiac 
effects.73-76 
 
Renal denervation and its effect on hypertension  
The hypothesis that denervation of the renal sympathetic nerves results in blood pressure 
reduction was successfully tested in unblinded clinical trials without a sham-control 
procedure. In humans, non-selective surgical splanchnicectomy, which includes RD, was 
frequently performed as primary hypertension treatment77, but unacceptable iatrogenic side-
effects, e.g. impotence, orthostatic hypotension and incontinence, led to its disappearance 
from current-day practice. The advent of endovascular therapy made access to the renal 
arteries and nerves possible through femoral artery puncture. Radiofrequency heat energy is 
applied through a dedicated helical catheter to sear and destroy the adventitial renal nerves 








Heradien et al. recently reported that RD could also be performed via brachial or radial artery 
puncture (Addendum).78 This form of RD vascular access eliminates the risk of groin-related 
hypertensive arterial bleeding and allows same-day hospital discharge. Although RD aims to 
essentially reduce brain-kidney sympathetic crosstalk, most of the experimental and clinical 
data we have to date focus on the ability of RD to reduce blood pressure. 
 
Landmark RD trials 
The series of landmark endovascular RD trials are often colloquially referred to as the 
‘Symplicity HTN Trilogy’. The first trial that kindled interest was published a decade ago. 
SYMPLICITY HTN-1 was a multicentre, non-randomised, safety and proof-of-principle cohort 
Figure 5. Renal denervation performed with a Symplicity Spyral catheter via 






study.79 Patients with so-called “resistant HT”, defined as an office BP ≥ 160/90 mmHg 
on three antihypertensive drugs including a diuretic, underwent percutaneous bilateral RD. 
Compared to baseline, office blood pressure at six months follow-up (6MFU) was reduced by 
22/11 mmHg. Importantly, renal noradrenaline spillover was reduced by 47% (95% CI: 28–
65%), signifying that RD treatment is associated with a reduction in sympathetic tone. 
 
SYMPLICITY HTN-2 was the first randomised controlled trial (RCT) that tested the hypothesis 
that RD was superior to medical therapy in the management of resistant HT.80 Again, even 
more impressive than in HTN-1, office systolic BP was reduced with RD by 32 mmHg at 6MFU. 
This trial resulted in an all-time high interest that RD might add an important new weapon in 
the fight against hypertension. Whereas the procedure was registered for use in European 
countries, the FDA insisted on a further trial before registration in the USA; hence, the 
SYMPLICITY HTN-3 trial was designed.81 
 
SYMPLICITY HTN-3 randomised 535 treatment-resistant hypertensive patients to RD or 
sham-RD. The results were interesting, but unexpectedly disappointing. Although both groups 
had significant office blood pressure reductions at six-month follow-up, RD did not meet the 
primary efficacy endpoint of superior office blood pressure reduction, compared to a sham-
RD procedure. These surprising results brought the “speeding RD train to a grinding halt”.82 
However, several confounders have been identified that may have contributed to the failure 







Possible confounders in HTN-3 
Despite a rigorous trial design and execution, several unaccounted factors may have 
contributed to HTN-3’s failure to demonstrate RD efficacy relative to sham control.83 These 
include patient demographics, medication adherence, “Hawthorne effect”, placebo effect, 
trial conduct, regression to the mean, operator experience and catheter design. 
 
Patient demographics 
Unlike previous SYMPLICITY trials, HTN-3 also recruited African American (AA) patients (26% 
of the prospectively stratified cohort). Compared to the non-AA sub-group, AA patients in the 
sham group had a 9.2 mmHg greater decline in office systolic blood pressure (SBP) at 6MFU. 
This change in sham office SBP was nearly twice as large in AA compared to non-AA patients. 
In a post-hoc analysis, the authors concluded that this unexpected BP reduction in the sham 
group is likely due to increased post-randomisation medication adherence and that the 
change after renal denervation was probably not confounded by race.84 Although this 
exploratory report does not provide definitive evidence that the SBP response to RD differed 
by race, it is generally accepted that hypertensive patients of African ancestry are poor 
responders to angiotensin-converting enzyme (ACE)-inhibitor and BB therapy.85 This view was 
recently challenged in the Creole study where investigators found that Black Africans respond 
better to perindopril-amlodipine than to perindopril-thiazide combination therapy.86 Despite 
these encouraging results that Black Africans may respond to ACE-inhibitor therapy, it 
remains to be proven that Blacks are poor RD responders.  
 
The beneficial effects of RD may be attenuated in patients with late-stage peripheral artery 




remodeling following the procedure. Indeed, several reports indicate that various indices of 
increased arterial stiffness predict improved blood pressure response following RD.87-89 
Likewise, Ewen et al. showed in a retrospective analysis that patients with isolated systolic 
hypertension, a coarse but easily-determined identifier of increased arterial stiffness (defined 
as office SBP > 140 mmHg and DBP < 90 mmHg), had less pronounced blood pressure drops 
than patients with combined systolic and diastolic hypertension.90 For this reason, patients 
with isolated systolic hypertension were explicitly excluded from the sham-controlled 
randomised controlled trials (RCTs) that followed SYMPLICITY HTN-3.  
 
Medication adherence 
Although patients were encouraged to continue taking their prescribed medication diligently 
throughout follow-up, urine or blood levels of anti-hypertensive drugs were not measured in 
SYMPLICITY HTN-3. Surprisingly, about 40% of the patients changed their antihypertensive 
medication regime after randomization. Non-adherence may be due to multiple factors 
including lack of understanding the risks and benefits of hypertension therapy, socioeconomic 
factors limiting drug access, social support, depression and anxiety and regimen complexity 
and side effects. Taken in context with the significant drop in blood pressure in the sham 
group, it is reasonable to suspect that unpredictable variable adherence to antihypertensive 
medication may have impacted the results of SYMPLICITY HTN-3. This concern led to the 
design of “off-medication” trial designs following SYMPLICITY HTN-3.  
 
Hawthorne and placebo effect  
The Hawthorne effect describes the adjusted behaviour of trial participants to seemingly 




medication adherence and patients reducing their salt intake and exercising more regularly. 
It is difficult, if not impossible, to prevent this type of behaviour. The placebo effect may also 
have played a large role in SYMPLICITY HTN-3, resulting in a significant reduction in office SBP 
in the sham group. 
 
Regression to the mean (RTM) 
RTM is defined as the tendency for an extreme measurement on one occasion to become less 
extreme when measured again. This may explain why, unlike previous SYMPLICITY trials, 
HTN-3 showed only a 4.1 mmHg between-group SBP treatment difference. To reduce this 
problematic statistical phenomenon, statisticians recommended that, rather than a Student 
t-test, analysis of covariance (ANCOVA) might be a more appropriate test to use in future RD 
trials.92 Finally, it is essential to note that the potential biases introduced by both the 
Hawthorne effect and regression to the mean can be addressed by randomisation. 
 
Operator experience and Catheter design 
In Symplicity HTN-3, 112 operators performed an average of 3.3 procedures per operator.78 
Less than five procedures were performed per site, and > 50% of the operators performed 
£ 2 procedures in the trial. Several technical challenges may face an inexperienced operator: 
difficult intubation with poor guide catheter back-up, accessory polar renal arteries (smaller 
than main vessel) that could not be treated, the "hostile" groin, e.g. morbid obesity and 
inability to visualize anatomically whether a successful 4-quadrant ablation was performed, 
using a 2D fluoroscopic image. Operators were also instructed to avoid distal renal arteries. 
However, Sakakura et al. subsequently discovered that in human cadavers, the renal nerves 




vs 3.4 mm).93 These sites, although being typical “sweet spot targets” for denervation, were 
thus missed in most cases. Animal studies have shown that RDN success is very much 
dependent on distal denervation.94,95 
 
The Flex catheter (Medtronic Inc.) is a single point denervation system that uses a proprietary 
algorithm of retraction, flexion and rotation to focus radiofrequency energy points in 
recommended anatomical sites of the renal artery. The Medtronic flex catheter was similar 
although apparently not identical to that used in the SYMPLICITY 1 and 2 trials which 
demonstrated approximately a 30mmHg drop in office systolic blood pressure. It was 
technically challenging to perform enough 4-quadrant ablations with the old catheter, but the 
next generation Symplicity Spyral catheter (Medtronic, Inc), which is an over-the-wire system, 
is a safer, more intuitive system than not only associates with more 4-quadrant ablations but 
also enables the operator to safely perform distal ablations, without the danger of perforation 
or dissection (Figure 6).  
 
The Spyral system typically requires less fluoroscopy time with less ionizing radiation and 
lower doses of iodine contrast agent resulting in better renal function outcomes post-
procedurally. Although the Spyral system measures vascular impedance as a surrogate 
marker of adventitial neural damage, a reduction in vascular impedance does not necessarily 






A new generation of sham-controlled renal denervation RCTs 
Recently reported positive results from three new randomized sham-controlled trials might 
have rekindled interest in RD. All three trials were designed to compensate for the 
confounding factors identified in HTN-3. Although smaller in scope than HTN-3, the sham-
controlled SPYRAL HTN-OFF MED trial tested the hypothesis that RD would reduce BP in the 
absence of anti-hypertensive drugs.96 Patients with milder HT were asked to discontinue their 
BP medication for at least one month before and during the trial duration. Similar to HTN-3, 
patients were randomised to RD or sham-RD. Compliance was checked with urine drug levels 
throughout the trial. RD was performed by experienced proceduralists, who also denervated 
Figure 6. Radio-frequency heat energy is applied for one minute with a Symplicity 
Spyral catheter* to sear the adventitial renal sympathetic nerves. (*Medtronic® -  





the distal renal arteries with a second-generation quadripolar catheter (Symplicity Spyral). 
Results were reported at three months and, albeit to a lesser degree than previous trials, 
showed that RD reduced office and ambulatory BP in hypertensive-drug naïve patients more 
than a sham-RD procedure, thus confirming the proof-of-concept.  
 
The sham-controlled SPYRAL HTN-ON MED trial showed similar, if not greater, improvements 
in both office and 24-hr blood pressure six months post-RD in a similar population treated 
with one to three antihypertensive agents.97  
 
Finally, the sham-controlled RADIANCE-HTN SOLO trial employed a design quite similar to 
SPYRAL HTN-OFF MED but used an ultrasound-based catheter denervation system 
(Otsuka/ReCor Paradise).98 The trial recruited 146 patients and patients were to remain off 
antihypertensive medications throughout the two months of follow-up. Interestingly, this 
catheter is only advanced into the main vessel, not into the distal renal arteries. The results 
after two months showed a significant reduction in daytime systolic ambulatory blood 
pressure and no major adverse events were reported in either group.  
 
Together, these trials energised endovascular RD and provided the much-needed hope that 
RD does lower blood pressure in selected patients when the right technique is used by 
experienced renal denervationists. Typically, the best responders to RD would be patients 
with chronically increased IST e.g. resting heart rate > 75 beats/min in BB-naïve patients or 





One of the major limitations of our current knowledge base is that we are unable to identify 
RD responders from non-responders with any degree of accuracy.   
 
Is there a knowledge gap: does RD have anti-fibril latory potential? 
In the past, most RD trials have focused on blood pressure-lowering, hoping that RD will 
provide the cure for the “silent killer”. Very little data, however, have been reported about 
the anti-arrhythmic potential of RD, and specifically the feasibility of RD used as “upstream 
therapy” to prevent non-valvular AF.  
 
Anti-fibril latory effects of RD: animal data 
Canine studies with long-term intermittent atrial pacing suggest that RD induces morpho-
electrophysiological changes that modify the AF substrate.99 These animals underwent right 
ventricular pacing for three weeks at 240 bpm, which induced heart failure (HF) similar to so-
called “tachy-cardiomyopathy.” In dogs with HF randomised to RD, compared to dogs with 
HF without RD, it was more difficult to induce AF during ganglionated plexi stimulation. One 
year later, the same group showed in a model of intermittent atrial pacing (8 hours/day for 
12 weeks) that left atrial structure and function were significantly improved in the RD group, 
compared to the sham group and that atrial fibrosis was also significantly reduced in the RD 
group.100 RD dogs had significantly fewer AF incidents and shorter AF duration. Compared to 
sham-control dogs, electrophysiological changes in RD canines included an increased atrial 







Anti-fibril latory effects of RD in humans 
Meta-analyses of human studies have shown that RD is associated with regression of both 
left ventricular hypertrophy (LVH) and left atrial dilatation.101 Meta-regression analysis, 
however, failed to demonstrate a significant relationship between RD-induced LV mass index 
reduction and BP at lowering at six months. This finding suggests that regression of LVH seen 
with RD may occur independently of BP changes. Recently, a small RCT showed that RD may 
reduce AF triggers and AF burden in patients with hypertension and paroxysmal or persistent 
AF.102   Pokushalov, et al. was the first to demonstrate that, when RD is added to PVI, incident 
AF is reduced.103 The trial recruited 27 patients: 9 of 13 (69%) who had RD were AF-free one 
year after PVI, compared to 4 out of 14 (29%) who did not have RD (p = 0.033). Several points 
of criticism were raised in a letter to the Journal editor: the main concern was the small 
sample size.104 Other concerns included changes in design and inclusion and exclusion criteria 
e.g. AF recurrence at one year was not a prespecified endpoint and a lack of detailed methods 
description e.g. the type of catheter used to stimulate the renal nerves. Five years later, the 
same group showed similar results after unconventionally combining data from two RCT’s: 
this time AF burden was confirmed with an implantable cardiac monitor.105 To date, no RCT 
has tested the feasibility of upstream RD treatment as a stand-alone therapy (without PVI) to 
prevent AF in patients with HHD. 
 
PROBLEM STATEMENT 
RD treatment may prevent non-valvular AF in patients with HHD. 
 
RESEARCH QUESTION 









To investigate the efficacy of RD as an anti-arrhythmic tool to preventing non-valvular AF in 




1. Demonstrate that RD treatment reduces incident, non-valvular AF in patients with 
hypertensive heart disease (primary efficacy endpoint). 
2. Demonstrate that RD treatment is associated with secondary endpoints, including:  
a. reducing office blood pressure six months follow-up (6MFU)  
b. reduced cardiovascular events including cardiovascular death and myocardial 
infarctions 
3. Demonstrate that RD treatment is associated with restoration of autonomic 
imbalance by: 
a. reducing resting heart rate at 6MFU 































STUDY DESIGN  
Pre-specified outcomes 
It was hypothesised that RD can prevent AF (primary efficacy end point) in patients with HHD. 
For this prespecified, primary endpoint a prospective, single-blind, randomised, sham-
controlled trail was designed. Although the study was not powered to detect a statistically-
significant difference in secondary end points, restoration of autonomic imbalance, 6MFU 
office and ambulatory blood pressure and cardiovascular endpoints (cardiovascular death, 
myocardial infarction [non-ST elevation and ST-elevation myocardial infarction with troponin 
leaks] and stroke [permanent neurological deficit] or transient ischemic attack [transient focal 
neurological deficit of < 24 hours duration]) were also assessed. It was also of interest to 
report the effect of RD on echocardiographic parameters, ECG-derived markers of autonomic 
tone and cardiac arrhythmia burden at 6MFU. 
 
Sponsor/ethical approval/study number/informed consent 
Medtronic (Inc.) sponsored the trial and provided renal denervation catheters, implantable 
loop recorders and patients transport fee reimbursement. The sponsor did not have access 
to the data. The study was approved by the Health Research Ethics Committee (HREC) of 
Stellenbosch University and allocated the study number M12/10/049. The study complied 
with the guidelines and stipulations of the Helsinki Declaration. Annual reports had to be 
submitted to the HREC regarding adverse outcomes, including death, withdrawal from the 
study or study-associated complications. Eligible patients provided written informed consent 
and could withdraw from the study at any time. Treating physicians were informed that their 




to take their medication regularly, but pill counts or urine drug levels were not performed to 
ascertain drug adherence.  
 
Clinical history and physical examination 
Every patient underwent a clinical history taking (anamnesis) and physical examination before 
randomisation. Patients were questioned about dyspnea grade and precipitants, angina, 
palpitations or leg swelling. Diabetes mellitus status, statin, aspirin or warfarin usage, 
previous coronary artery disease (CAD) (previous myocardial infarction, stents or coronary 
artery bypass surgery), previous stroke (embolic or hemorrhagic) or transient ischemic attack 
(reversible neurological deficit that disappeared in 24 hours), peripheral arterial disease 
symptoms (claudication, rest pain, etc.) were ascertained. Although most people with sleep 
disorders are often undiagnosed, patients using continuous positive airway pressure (CPAP) 
devices were regarded as having obstructive sleep apnea. Patients were asked about previous 
cardiac arrhythmic events (e.g. atrial flutter or fibrillation; ventricular tachycardia), electrical 
or chemical cardioversion and the use of anti-arrhythmic drugs. Patients were also asked 
about allergies against penicillin and iodine (used during angiography).  
 
Peripheral pulses were palpated and the carotid pulses auscultated for bruits and palpated 
for volume and pulse wave characteristics. If pulses were of equal volume in both arms, blood 
pressure was taken on the left upper arm with an automated device (Omron M3) and a large 
cuff after five minutes of rest. The apex beat was palpated and a heaving apex beat was 
indicative of clinical left ventricular hypertrophy. The heart was auscultated for the presence 
and loudness of S1 and S2, additional cardiac sounds and audible murmurs, respectively. The 




a pulsation that may indicate an abdominal aortic aneurysm, auscultated for bruits indicative 
of renal artery stenosis and fundoscopy performed to look for signs of hypertensive or 
diabetic retinopathy. Urine dipstick tests were performed to exclude proteinuria, glycosuria 
or hematuria. Urine was sent to the laboratory for microscopy, culture and sensitivity, if 
positive on dipsticks for leucocytes or nitrites.  
 
Due to funding limitations, this investigator-driven, single site pilot study did not have a data 
and safety monitoring board (DSMB). Furthermore, a DSMB was not an ethical pre-requisite. 
 
Special investigations 
Every screened patient underwent a standard transthoracic echocardiogram performed by 
experienced cardiac technicians who were blinded to the patients randomisation status. 
Echo-images were captured with a VIVID (General Electric) echo machine in the parasternal 
long and short axis and apical two-and four-chamber views. Images were saved electronically 
for further analysis. Patients underwent a standard Bruce-protocol treadmill exercise stress 
test (EST). Blood pressure was taken every minute during and after the test using an 
automated blood pressure cuff. The EST was terminated if the patient reached at least 80% 
of their target heart rate or developed tiredness with the inability to exercise further. Patients 
experiencing chest pain, hypotension, significant cardiac arrhythmias or ST segment shifts 
during/immediately after the test were considered to have a poor prognostic stress ECG test 
requiring invasive coronary angiography. Qualifying patients were also fitted with a 24 hr 
ambulatory ECG recorder and automated blood pressure monitoring (ABPM) device 
(Mortara) for home heart rhythm and blood pressure monitoring, respectively. Data obtained 




patient’s randomisation status. Baseline blood tests included sodium and potassium serum 
level and an estimated glomerular filtration rate (eGFR). Patients fulfilling all the inclusion 
criteria were invited to participate in the study and asked to sign an informed consent. Those 
with any exclusion criteria were thanked for their screening visit, but not included in the 
study. 
Inclusion Criteria: 
1. Age ≥ 55 years 
2. Office blood pressure ≥ 160/90 mmHg in non-diabetics or ≥ 150/90 mmHg in diabetics 
3. Subjects must be on at least three anti-hypertensive drugs, including a diuretic agent 
4. Sinus rhythm  
5. Left ventricular hypertrophy defined on echo defined as: 
a. Estimated LV mass > 255 g or LVMI > 115 g/m2 for men 
b. Estimated LV mass > 193 g or LVMI >95 g/m2 for women 




6. Must have an indication for coronary angiography with a positive stress ECG 
with/without angina or angina equivalent e.g. dyspnea. A positive stress ECG was 
defined as ≥ 1 mm ST segment shift (depression or elevation) in ≥ 2 contiguous leads. 
 
LV Mass (g) = 
 





7. Evidence of left atrial dilatation, defined as a left atrial diameter of ≥ 45mm on either M-
Mode or two-dimensional (2D) measurement or a Left Atrial Volume Index (LAVI) ≥ 34 ml/m2, 
which was calculated by determining the left atrial area in the apical four- chamber and two-
chamber views, respectively. This product was then multiplied by 0,85 and divided by the 
shortest perpendicular distance from the coaptation point of the mitral valve leaflets 












1. Estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2 
2. Renal artery anatomy unsuitable for RD 
3. Significant valvular heart disease e.g. moderate/severe valve stenosis or regurgitation 
5. Untreated thyroid disease, e.g. thyrotoxicosis 
6. Patients needing to undergo coronary artery bypass surgery 
 
Randomisation 
Consenting patients were randomised using a computer-generated number sequencer 
(https://numbergenerator.org/) and a closed envelope system. Although the patient was 
blinded, only the researcher was aware of whether the patient had been allocated to the 
active or sham RD arm. Allocation status was only revealed to the patient at the end of the 
study or during life-threatening emergencies, e.g. severe hypotension or hypertensive 
emergencies. 
 
Definition of autonomic imbalance 
Autonomic imbalance (AI) was defined as the presence of one or more risk factors being 
present:  
1. resting heart rate (RHR) >75bpm, signifying IST  
2. peak exercise heart rate minus one minute exercise recovery heart rate (HRR) 







Statistical considerations: sample size calculation and between-group comparisons 
The Stellenbosch University Department of Biostatistics assisted with statistical calculations 
which were performed with SPSS software (IBM Corporation). No study was previously 
published on upstream preventative treatment of AF. The main screening purpose was to 
recruit a study population with a relatively high risk to develop AF that can be detected by 
an implantable cardiac monitor over a relatively short period of time. In this regard, older 
people with hypertension, coronary artery disease and HHD (left ventricular hypertrophy and 
left atrial dilation) were considered ideal candidates for the study. The ASSERT study 
investigated the incidence of device (pacemaker or implantable cardioverter defibrillator)-
detected subclinical AF (SAF) and the risk of stroke in older, hypertension-treated patients.106 
The 3-month SAF incidence was 10.1%. SAF incidence in the present study was predicted in 
40% in the sham group after a three-year follow-up and of 10% in the RD treatment group, 
respectively. Power was set at 80%, alpha at 0.05 (probability of a type I error) and beta at 
0.2 (probability of a type II error). This resulted in a sample of 31 patients in each arm (n = 62). 
The sample size was increased to 90 patients to account for loss to follow-up and attrition, 
study-withdrawal and death. Subsequent to the current study protocol which was 
conceptualised in 2013, Reiffel et al, reported in the REVEAL AF study an event rate of 40% at 
30 months in patients without avert atrial fibrillation who had an implantable loop recorder 
placed.107  This information was not available at study conception, but seems to support the 
sample size calculation. The log-rank test was used to calculate the cumulative incidence of 
the primary endpoint with a Kaplan-Meier graph. Analysis of covariance (ANCOVA) and 
student’s t-test (paired and unpaired) were used to compare means intra-group (baseline vs 
6-month follow-up) and between groups, respectively. Fisher’s exact test was used to 




INTERVENTIONAL PROCEDURES  
 
Diagnostic coronary angiogram 
Non-fasting patients were admitted to a general medical ward and instructed to take his/her 
regular medication. To reduce the risk of iodine contrast-nephropathy, the patient was pre-
treated with one liter of normal saline over four hours. The patient was given a mild oral 
sedative (Lorazepam: 1 mg sublingually) in the ward before transfer to the cardiac 
catheterisation laboratory. ECG monitor stickers and an automated blood pressure cuff were 
placed on the patient's contralateral arm (arm not used during coronary catheterisation). The 
patient's right groin area and right forearm were shaved and cleaned with Hibitane® cleaning 
solution. The patient's left forearm was only prepared if he/she previously had coronary 
artery bypass surgery to enable intubation of the left internal mammary arterial graft. The 
patient was covered with a sterile drape.  
 
The skin over the radial artery was injected with 5% Lignocaine and the radial or femoral 
artery punctured with a sterile, hollow steel needle. The modified Seldinger technique was 
then used to canalise the artery. After inserting a sheath into the radial artery, if used for 
arterial access, it was flushed with a mixture of nitrates, Verapamil and heparinised saline. 
Coronary angiography was performed using either a 5 French diagnostic Tigue catheter (radial 
artery) or 6 French diagnostic left and right Judkins catheter (if the femoral artery was 
punctured). Significantly narrowed epicardial arteries with a lumen diameter narrowed ≥ 70% 
were treated according to the performing cardiologist's judgement. Complex CAD for possible 






Both renal arteries were injected with iodine-containing ionizing contrast dye to delineate its 
anatomy and ascertain the presence of accessory renal arteries. 108 After pre-treatment with 
5 ml of nitrates intra-arterially and 5000 IU heparin intravenously, a balanced middleweight 
guidewire (BMW; Abbot) was threaded through a short 6-French Amplatz guiding catheter 
down the renal artery under X-ray fluoroscopic guidance into the distal renal artery branches. 
In patients randomised to active treatment, the quadripolar, Symplicity Spyral renal 
denervation catheter (Medtronic Inc.) was threaded over the guidewire into a distal renal 
artery. The guidewire was pulled back into the guiding catheter, and the denervation 
conformed to the vessel wall in a spiral fashion, hugging the vascular endothelium (Figure 6, 
above). Radiofrequency heat energy up to 70 °C was applied for one minute after giving the 
patient 2 ml of intravenous morphine sulphate (10 mg/10 ml) for analgesia. The guidewire, 
which was withdrawn into the main renal artery, was threaded back over the denervation 
catheter. The guidewire was then steered into another distal artery attempting to denervate 
each distal polar artery with at least four denervation sites. Finally, the main vessel was 
treated with at least eight denervation sites. The same procedure was repeated on the contra-
lateral or accessory renal arteries.  
 
Sham renal denervation 
In patients randomised to the sham-arm, contrast dye was injected into the renal artery, but 
the guidewire was not passed down the artery. Pre-recorded renal denervation machine 
sounds were played during the sham procedure and saline was injected as a mock painkiller, 





After both renal arteries were treated, the guide catheter and guidewire, if used, were 
removed and the puncture site was either sealed with an Angioseal® closure device for 
femoral artery punctures or compressed with an inflatable armband (Terumo®) for radial 
artery punctures. 
 
Insertion of implantable loop recorder (ILR) 
Every patient, regardless of randomisation allocation, had a subcutaneous ILR (Reveal XT: 
Medtronic) implanted upon completion of the vascular intervention. The skin over the sternal 
area was sterilized with Hibitane solution, and the parasternal left fourth intercostal space 
was infiltrated with 5% Lignocaine. A 2 cm-incision was made over this space and anchoring 
sutures were placed at opposite angles of the wound. The ILR was inserted subcutaneously 
and tied to the anchoring sutures to prevent dislodgement. The subcutaneous layer and skin 
were sutured separately with chromium and nylon (V-lock®), respectively. Every patient was 
given 2 g of intravenous Cefazolin to reduce the risk of skin infection. The wound was covered 
with a waterproof, sterile plaster (Opsite®), and the patient instructed not to remove the 
plaster until two weeks have passed. The patient was taken back to the general medical ward, 
the saline infusion was completed, and the patient was discharged the same day if he/she 
had a radial procedure. Patients who had a femoral arterial puncture were observed 
overnight in the general medical ward.  
 
Follow-up 
Patients who were referred for coronary artery bypass surgery remained included in the trial. 
Patients were followed up at six-monthly intervals for the primary efficacy end point, by 
scanning the ILR and performing a 12-lead ECG with each visit. Prespecified secondary 









































Recruitment and randomisation  
Between 1 March 2013 and 31 August 2018, a total of 800 patients were screened for 
eligibility, out of which 717 patients did not meet the entry criteria or declined to participate 
(Figure 8). Eighty-three patients were randomised, one patient in the RD group withdrew 
informed consent and one patient in the sham group could not be traced: complete data sets 
were available for 80 patients (RD: 42 and sham RD: 38).  
 
 
BASELINE CHARACTERISTICS  
Figure 8. Recruitment, randomisation, follow-up and analysis of data of patients recruited 
for the study. Although 39 patients were allocated to sham-RD treatment, one patient 






Baseline characteristics were similar across the study groups (Table 1). Participants with male 
sex were more prevalent in both groups. Most of the subjects were obese (BMI > 30 kg/m2) 
with a central obesity distribution. Participants with white race were more prevalent (56%), 
followed by mixed race patients. (41%). Blacks were under-represented in the study (3% of 
the study population).  
 
More than half of the population (56%) were diagnosed with obstructive sleep apnoea and 
16% had previous strokes/transient ischemic attacks. Peripheral arterial disease was 
prevalent in 11% of the total study population. Type 2 diabetes mellitus prevalence was 54%; 
88% of the study cohort took statins and 13% were current smokers.  
 
Overall, 28% of the patients reported previous episodes of AF. The CHA2DS2-VASc score, 
which is used to assess which patients should be treated with oral anti-coagulation when they 
develop AF, did not differ between groups and at baseline; 12% of the study population were 
prescribed an oral anti-coagulant (warfarin or novel oral anti-coagulant) by their treating 
physicians.  
 
Coronary artery disease (CAD), confirmed during coronary angiography, was prevalent in 68% 
of patients and 26% of patients had previous myocardial infarctions. Triple vessel CAD was 
present in 24% of the overall cohort and the European Heart SCORE did not differ significantly 
between groups (Table 2). None of the patients had an acute coronary syndrome the day 














Office blood pressure and anti-hypertensive treatment 
Baseline office systolic blood pressure was 147.5 ± 21.2 mmHg for the study population and 
did not differ between groups (RD: 149.9 ± 20.6 mmHg vs 146.3 ± 22.2 mmHg; p = 0.454). 
Although 22 of 80 patients (28%) had an office SBP < 140 mmHg, 37 ± 27% of their ambulatory 
SBP measurements were > 140 mmHg, confirming the diagnosis of baseline uncontrolled HT.  
The average number of anti-hypertensive drugs (RD: 3.57 ± 0.91 vs sham: 3.89 ± 1.11; 
p = 0.161) and drug class were not different. ACE-inhibitors were more frequently prescribed 
than angiotensin-receptor blockers. Beta blockers were more frequently prescribed than 




LV ejection fraction, LA dimension or LAVI did not differ between groups. LV mass was heavier 
(30 g) in the sham compared to RD group (p = 0.051). LVH was non-significantly more 
prevalent in the sham group (68% vs 48%; p = 0.073), but the non-invasive marker of diastolic 







Overall, ten patients (12.5%) were revascularized: three patients in each group received intra-
coronary stents in and two patients in each group were referred for bypass surgery. In four 
patients (9.5%) RD was performed via brachial or radial artery puncture, the rest was treated 
femorally. Two of 42 patients (4.8%) had accessory renal arteries that were ablated during 
the same procedure. RD patients underwent 24 ± 9 ablations during 26 ± 9.7 minutes and on 
average, 16 ablations were safely performed in the branch arteries after the renal artery 
bifurcation.  
Primary endpoint: Subclinical Atrial Fibrillation (SAF) 
 
After three years average follow-up, fewer RD patients experienced SAF: 6 of 42 RD patients 
(14.3%) vs 15 of 38 (39.5%) sham patients (odds ratio [OR], 0.256, 95% confidence interval 
(CI), 0.087–0.754; p = 0.012) (Figure 9). 
 
Figure 9. Cumulative incidence of subclinical atrial fibrillation. Patients with 






The absolute SAF risk reduction was 25.2% and four patients had to be treated with RD to 
prevent one SAF event. SAF relative risk was reduced by 64% with RD compared to the sham 







Fast AF, defined as a ventricular rate of ≥ 100 bpm on the 12 lead ECG or implantable loop 
recorder, was significantly more prevalent in the sham group (10 of 38 (26.3%) vs 1 of 42 
(2.4%); OR, 14.64; 95% CI, 1.77–120.91; p = 0.002). Compared to patients who underwent a 
sham RD procedure, the relative risk to experience fast AF after RD was reduced by 91%. Every 
patient with fast AF were considered to be in “clinical AF” and were symptomatic and 
admitted for urgent cardioversion. Stratification for prior AF and its recurrence was not 
performed because not every subject have reached the three year follow up point yet. 
 
Figure 10. Relative risk of atrial fibrillation (AF) in hypertensive heart disease patients 




SECONDARY ENDPOINTS  
Office blood pressure  
Systolic office blood pressure (SBP) between groups did not differ at baseline but was 
significantly reduced at 6MFU in patients randomised to RD (148.76 ± 20.42 mmHg to 
136.37 ± 16.91 mmHg: −12.88 ± 20.64 mmHg reduction; p = 0.0003). There was also a trend 
of SBP reduction in sham subjects (−9.13 ± 25.22 mmHg reduction; p = 0.053). The between-






Similarly, office diastolic blood pressure (DBP) was significantly reduced following RD 
(−6.2 mmHg; p = 0.003), but not in the sham group (−3.9 mmHg; p = 0.17). The between-
group 6-month DBP difference of −2.3 mmHg was not significant (p = 0.49).  
 
24hr-Ambulatory blood pressure  
All variables included in this analysis were normally distributed. Thirty-four ambulatory BP 
measurements could be analysed: 20 in the RD group (48%) and 14 in the sham group (37%) 
(Table 3). This implied that more than half of the study population (57%) had either 
uninterpretable or absent ABPM measurements. ABPM measurements did not differ 
between groups at baseline. The baseline prevalence of isolated systolic hypertension was 







The change in ambulatory SBP did not differ within or between the groups (-4.1mmHg; 













At an average of three years follow-up, cardiovascular death incidence was significantly lower 
in the RD group compared to sham RD (1 of 42 [2.4%] vs 6 of 38 [15.8%]: OR, 0.13, 95% CI, 






The relative risk of cardiovascular death was non-significantly reduced by RD with 85% (RR, 





Chest pain syndromes 
Unstable angina 
During follow-up, 23 of the 80 study patients (29%) experienced an acute coronary syndrome 
(ACS) requiring hospital admission (Table 4). Fourteen patients had unstable angina with 
persistently negative cardiac troponins: five (12%) in the RD group and nine (24%) in the sham 
group. The incidence of unstable angina did not differ between groups (OR, 0.43; 95% CI, 





Table 4. Incidence of pre-specified, secondary cardiovascular endpoints in 
patients randomised to renal denervation (RD) or a sham procedure. NSTEMI 
denotes non-ST elevation myocardial infarction and STEMI denotes ST-




Myocardial infarction (NSTEMI and STEMI) 
Eight patients had positive cardiac troponins without ST-segment elevation (NSTEMI) prior to 
coronary angiography: one in the RD group (2.3%) vs seven in the sham group (18.4%) 
(OR, 0.11; 95% CI, 0.01–0.92; p = 0.02. Compared to sham treatment, the relative risk to 
experience an NSTEMI after RD was 0.129 (95% CI, 0.02–1.00). One patient in the sham group 
(2,6%) and none in the RD group (0%) experienced an ST-elevation myocardial infarction 
(p = 0.47).  
 
Pulmonary embolism 
One patient in each group had a non-fatal pulmonary embolism: 1 of 42 patients (2.4%) in the 
RD group and 1 of 38 (2.6%) in the sham group (OR, 0.9; 95% CI, 0.05–14.94; p = 1.00). Both 
were older men with permanent pacemakers and a history of previous deep venous 
thrombosis. Both patients were started on warfarin aiming for a therapeutic INR of 2–3. They 
did not experience any further complications. 
 
Neurological events 
During follow-up, five transient ischemic attacks occurred in four RD patients (9.5%) and 
one sham patient (2.6%), respectively (OR, 3.89; 95% CI, 0.42–36.50; p = 0.36). None of these 
patients had an intracranial haemorrhage or signs of raised intracranial pressure on their 
admission CT brain scan. They were not treated with intravenous thrombolytic drugs, but 
their neurological signs disappeared completely within 24 hours. These events were thus 
regarded as “embolic” and patients with SAF on their ILR, were started on life-long warfarin, 




with dual-anti-platelet therapy for six months, after which clopidogrel was discontinued and 
aspirin continued for life. 
 
Echocardiographic parameters that may be influenced by RD  
6MFU echocardiographic data were available for 68 of 80 patients (85% of total population) 






Table 5. Between-group difference of pre-specified echocardiographic 




LV ejection fraction 
Baseline LV ejection fraction (LVEF) did not differ between groups (Table 1). At 6MFU, 38 RD 
patients experienced a nonsignificant LVEF increase of 0.66 ± 5.78% vs 0.23 ± 7.98% increase 
in 30 sham patients (p = 0.80). 
 
LV mass/LV mass index 
At baseline, LV mass was heavier and LVH significantly more prevalent in the sham than RD 
group (Table 1). At 6MFU, LV mass (LVM) decreased non-significantly in both groups, but 
more in the sham group: RD: −4.30 ± 48.73 g vs sham: −8.94 ± 59.10 g; p = 0.72. More than 
half of the patients in each cohort experienced a reduction in LVM: 19 of 37 RD patients (51%) 
vs 19 of 33 sham patients (58%); p = 0.64. LV mass index (LVMI) was also non-significantly 
reduced in both groups (p = 0.50), but more in the sham group. 
 
Left atrial dimension/volume index 
At 6MFU, left atrial (LA) dimension was non-significantly reduced in both groups: RD: 
−0.76 ± 2.72 mm vs sham: −0.34 ± 2.40 mm; p = 0.50. More RD patients experienced a 
reduction in LA dimension at 6MFU: 16 of 38 RD patients (42%) vs 11 of 32 sham patients 
(34%); p = 0.62. LA volume index (LAVI) decreased non-significantly in both groups (p = 0.83). 
 
E/e’: A marker of diastolic dysfunction 
E/e’ values had a skewed distribution and data were analysed using a Mann-Whitney U test. 
E/e’ was non-significantly reduced in both groups (Figure 14). The between-group differences 
did not differ significantly (p = 0.71). The prevalence of diastolic dysfunction, defined as 








Resting heart rate (RHR)  
Resting ECG data of 41 RD and 36 sham patients, respectively, were analysed at baseline 
(Table 9). Baseline resting heart rate (RHR) did not differ between groups. After 6MFU, 











At 6MFU, RHR did not differ between groups (p = 0.96). More RD patients experienced a 
reduction in RHR at 6MFU compared to sham patients: 22 of 38 RD patients (59%) vs 10 of 28 
sham patients (36%); p = 0,0871. Contrary to RD patients, who had a mild reduction in RHR, 








24hr holter ECG Ambulatory heart rate 
Ambulatory heart rate (AHR) did not differ between groups at baseline (p = 0.53) or 6MFU 
(p = 0.92) (Table 9). Although average 6MFU AHR was reduced in the RD group (n = 35) and 
increased in the sham group (n = 30), the between-group difference was not significant 





























Figure 15. Change in resting heart rate (RHR). Time 1 represents baseline and 




One-minute Heart rate recovery post exercise (HRR) 
One-minute HRR did not differ between groups at baseline (p = 0.36) or 6MFU (p = 0.45), 
respectively. HRR increased in RD patients (n = 28) and decreased in sham patients (n = 22), 
but did not change significantly between groups over the 6MFU period (delta RD-change: 




Markers of autonomic imbalance 
RHR>75bpm and HRR<25bpm did not differ between groups at baseline at baseline or 6MFU, 
respectively: (RD: Sham RD; RHR>75bpm at 6MFU: 14% vs 11% ; p= 1.00; HRR<25bpm: RD: 




Heart rate variability: SDNN on 24hr holter ECG  
Overall, 49 of 80 patients (61%) had complete time domain HRV/standard deviation of normal 
to normal intervals (SDNN) measurements at baseline compared to 39 (49%) at 6MFU. 
Baseline SDNN did not differ between groups (RD: 96.54 ± 25.34 ms [n = 28] vs sham: 
104.76 ± 27.88 ms [n = 21]; p = 0.29). Sixteen of 28 RD patients (57%) vs 8 of 21 sham patients 
(38%) had a reduced SDNN < 100 ms at baseline (p = 0.25). At 6MFU, SDNN increased non-









Effect of RD on Cardiac Arrhythmia 
Supraventricular ectopy 
Supraventricular extrasystoles (SVES) could be assessed in 50 patients at baseline of whom 
28 (56%) were randomised to RD. SVES 24 hr-values had had a skewed distribution and 
ranged from 1/24 hr to > 9000/24 hr at baseline and 0 to > 3000/24 hr at 6MFU, respectively. 
At 6MFU, SVES could only be assessed in 35 patients of whom 19 underwent RD. RD non-
significantly associated with a trend towards lower SVES burden (p = 0.056), compared to 







Ventricular ectopic beats (VES) were detected in 51 patients at BL and 39 patients at 6MFU, 
respectively. VES also had a skewed distribution and could not be analysed with parametric 
tests. The 24 hr values ranged from 0 to > 1400VES/24 hr at baseline and 0 to > 2900/24 hr 






Effect of RD on QTc-interval  
The QTc-interval did not differ between groups at baseline (RD: 433.13 ± 35.39 ms vs sham: 
438.14 ± 28.71 ms; p = 0.51) or 6MFU (RD: 433.15 ± 27.50 ms vs sham: 444.56 ± 39.46 ms; 
p = 0.19).  
 
The prevalence of patients with a prolonged QTc-interval (>440 ms for males and >460 ms for 
females) did not differ between groups at baseline (14 of 39 RD patients [36%] vs 14 of 35 
sham patients [40%]; p = 0.81) or 6MFU (8 of 34 RD patients [24%] vs 7 of 27 sham patients 
[26%]; p = 1.00).  
 
After 6MFU, QTc was reduced in the RD group, compared to a non-significant increase in the 










































In this single-centre, single-blinded RCT, it was demonstrated that RD reduces subclinical AF 
and fast AF incidence in patients with HHD, independent of blood pressure lowering. RD 
treatment was also associated with a reduction in NSTEMI incidence and cardiovascular 
death. These novel findings have not been reported previously. 
 
Possible mechanisms of the anti-arrhythmic effect associated with RD 
The pulmonary veins and left atrium are richly innervated by autonomic nerve fibres.109 Pre-
clinical animal research suggests that RD-induced changes in atrial electrophysiology possibly 
contributes to the anti-fibrillatory mechanism by reducing atrial nerve sprouting and 
complexity of AF in goats.110 Median conduction velocity was higher and AF cycle length was 
shorter in RDN-AF compared with SHAM-AF. Wang et al. recently showed that RD via renal 
artery adventitial cryoablation induces fibrosis of the left stellate ganglion nerve fibres. 
Damage to this vital sympathetic nerve substation significantly reduced novel left atrial 
sympathetic nerve sprouting and AF inducibility in canines.111  
 
Peripheral parasympathetic stimulation may have similar effects. Stavrakis et al. reported 
that low-level transcutaneous electrical vagus nerve stimulation through a metal clip attached 
to the ear tragus suppresses AF in humans.112 These findings support the hypothesis that 
targeting the autonomic nervous system through peripheral manipulation may provide novel 
and beneficial anti-arrhythmic effects.113  
 
Steinberg et al. recently reported the results of the ERADICATE-AF trial, which tested the 




recurrence of AF.114 This multi-centre RCT was conducted in Russia, Poland and Germany and 
included 305 patients with PAF and hypertension. Baseline characteristics were well-
matched, and the mean PAF duration was 3.6 years. PVI was performed with a cryoballoon 
and successful ablation was confirmed with multi-electrode mapping. The one-year freedom-
from-AF rate was significantly higher in patients who underwent additional RD: 72.1% vs 
56.5%; HR 0.57; 95% CI 0.38 to 0.85. There were some safety concerns, however: the 
investigators used standard AF ablation catheters to denervate the renal nerves and not 
dedicated RD catheters. Major adverse events did not differ significantly between groups. 
ERADICATE-AF provides further evidence that RD has anti-fibrillatory effects when added to 
PVI. One of the concerns about this trial is that it was not definitive and carried out in a 
population with hypertension that was not well-controlled. 
 
The current study is first of its kind to suggest that RD could potentially be used as an 
upstream or stand-alone therapy to prevent AF in patients with HHD.  
 
RD and autonomic imbalance 
None of the proposed markers of cardio-autonomic tone (SDNN and heart rate profiles at 
rest, during ambulation and exercise) was significantly improved by RD in our study. Several 
confounders may have influenced these results, however.  
 
First, it is possible that these findings represent a type II statistical error underscoring 
insufficient power to test the proposed hypothesis that RD corrects autonomic imbalance.   
Second, there are currently no established normal HRV cut-off values for this older, obese 




feasibility of using other heart rate profiles (RHR, 24 hr AHR and HRR) to assess cardio-
autonomic tone (CAT). Ukena et al. recently reported that RD was significantly associated with 
reduced 24 hr ambulatory heart rate in patients with resistant hypertension who had a 
baseline HR > 72 beats/min.115 Similar to the current study, they also reported that RD was 
associated with a reduced supraventricular ectopic burden, but they could also not 
demonstrate improved HRV. This potentially important finding implies that RD either does 
not affect HRV, which is primarily under vagal control, or that RD only reduces acute 
adrenergic surges translating into beneficial anti-fibrillatory effects. Although it was probably 
sufficiently powered, the Ukena study may have some flaws. In their non-randomised 
prospective cohort study, patients acted as their own controls. Selection bias and the 
Hawthorne effect may also have influenced their results. A such, it is important to remember 
that their reported association does not necessarily prove causality and is subject to 
confounding. 
 
Finally, the high prevalence of concomitant BB therapy (> 75%) in a population with both HHD 
and CAD may have influenced the results of CAT testing. In this regard, HRR, which is purely 
under vagal control, was added to the autonomic tests. An improvement in HRR, albeit non-
significantly, reflects an improvement in parasympathetic tone, suggesting that reduced 
sympathetic tone through RD may indirectly increase inhibitory vagal cardiac reflexes. Larger 
randomised trails may provide an answer to this important question of RD can restore AI. 
 
RD is associated with reduced NSTEMI and cardiovascular death in patients with HHD 
Prospective randomised studies on the effect of RD on CAD have not been published before. 




cardiovascular death, there were non-significant signals that the relative risks of these events 
may be reduced after RD.  
 
Several mechanisms may explain this novel and unexpected finding of NSTEMI risk reduction. 
Atherosclerotic plaque rupture is central to the development of ACS. It is well-known that 
increased inflammation and a thin fibrous cap covering the atheroma increase the risk of 
plaque rupture and intravascular thrombosis. IST, which is characterised by reduced heart 
rate variability, is associated with increased levels of interleukin-6 and C-reactive protein 
(CRP).116 These mediators may trigger the release of metallo-proteinases from neutrophils 
which degrade the fibrous atheroma cap. IST also is associated with an increased thrombotic 
risk. The mediators of the stress reaction can directly affect platelets and the coagulation 
cascade.117 Reduced sympathetic tone may, therefore, reduce these pro-inflammatory 
processes which could potentially promote atherosclerotic plaque stabilisation. Similarly, 
statins reduce not only LDL-cholesterol and therefore plaque volume, but also high-sensitivity 
CRP.118 In our high-risk population, where more than 80% of the patients took statins for 
secondary prevention, NSTEMI relative risk was further reduced, albeit non-significantly, 
when RD was added to these preventative therapies. The large difference in NSTEMI is also 
most likely a play of chance due to small numbers, although it is reasonable to make the 
observation.  To this point, the pathophysiology of the reduction in NSTEMI by RD remains 
speculative, and this signal needs to be explored in larger, prospective trials. 
 
The finding that RD was associated with reduced cardiovascular death in patients with HHD 
is novel. Although every study subject had a normal ejection fraction at baseline, the study 




infarctions and LVH. These risk factors, coupled with ageing, may synergistically act to 
increase cardiovascular mortality. The reduced mortality signal with RD is encouraging, but 
the study was underpowered to detect a possible mortality benefit with RD, which should be 
assessed in larger high-risk populations. 
 
Office/Ambulatory blood pressure: baseline vs six months follow-up 
Similar to Symplicity HTN-3, this study could not demonstrate a superior office blood 
pressure-lowering effect with RD treatment over sham therapy. A similar effect was 
demonstrated when comparing 24hr ABPM between groups. Although the sample size was 
almost seven times smaller than HTN-3 (80 vs 535 study subjects), similar confounders may 
have influenced the blood pressure results.  
 
Adherence to blood pressure lowering therapy may have influenced the results119, but 
randomisation of study subjects should have reduced this confounder. The fact that patients 
only received light sedation during RD and could still experience RD-associated back and loin 
pain may have "unblinded" them and could have resulted in them cutting down or skipping 
their medication. Conversely, increased adherence in the sham group, on the other side, 
especially if study participants are told that their blood pressure is high by their general 
practitioners, may explain the drop in their 6MFU blood pressure. Although patients were 
encouraged to take their medication as prescribed, pill counts were not performed, and anti-
hypertensive drug therapy levels in urine or the serum were not checked. 
 
Finally, more recent BP-lowering trials have confirmed a significant, albeit smaller blood 




of 12 RCT's and > 1500 patients indicated that RD was associated with a significantly greater 
reduction of 24-hour ambulatory SBP and office SBP.120 Furthermore, RD was not associated 
with an increased risk of major adverse events supporting the notion that percutaneous RD 
is a safe procedure in the hands of experienced proceduralists. 
 
Echocardiographic parameters that may be influenced by RD 
Although the study sample was not powered to show significant echocardiographic changes, 
RD treatment was non-significantly associated with an increase in LVEF and a reduction in LA 
diameter. A reduction in LA size may lower left atrial pressure which associates with less 
stretch forces on the pulmonary venous ostia. Although E/e’, a non-invasive marker of 
diastolic dysfunction, was reduced in both study groups, RD did not lower E/e’ more than the 
sham procedure. The observation that sham-group LV mass was heavier at baseline may have 
influenced mortality outcomes121, although LV mass did decrease in the sham group at 6MFU. 
Unlike previous non-randomised trials, the study could not demonstrate significant 
regression of LVH at 6MFU in patients treated with RD.  More extensive randomised studies 
are needed to explore if RD can regress HHD and improve diastolic dysfunction. If positive, 
such a finding may be useful in the management of heart failure with a normal ejection 
fraction. 
 
RD treatment and supra-ventricular ectopic burden 
RD showed a statistical trend towards a reduction of SVES. Conversely, SVES increased with 
the sham procedure. An underpowered sample size limits further clinical extrapolation. This 
finding does, however, support the reported association between supra-ventricular ectopy, 




RD treatment and prolonged ventricular repolarisation 
The finding that RD was not associated with QTc-prolongation is reassuring. Conversely, RD 
was associated with non-significant QTc-shortening which may have beneficial effects on the 
management of malignant cardiac arrhythmias, e.g. polymorphic ventricular tachycardia. It is 
well known that left cardiac sympathectomy is protective in patients with LQTS.123 In a recent 
meta-analysis, Zhang, et al. found that AF risk increases with 17% for every 10 ms 
prolongation in QTc.124 This finding supports current thinking that neural mechanisms modify 
the arrhythmia risk in LQTS.65 RD treatment may potentially be useful to treat symptomatic 
long QT syndrome patients, or those suffering from recurrent implantable cardioverter-
defibrillator shocks or those with ablation-refractory ventricular tachycardia.125  
 
Usefulness/role of RD in future daily clinical practice  
RD-therapy is not ready for everyday clinical practice yet. The final blood-pressure lowering 
trial is eagerly awaited, but needs careful planning, circumferential ablation catheters and 
experienced operators to perform the procedure. The technique of RD is not difficult to 
perform and keen learners should be able to perform the procedure themselves after 
observing at least three cases. Left radial access avoids complicated groin punctures and 
subsequent bleeding complications. Unfortunately, the high cost of the catheters 
(R60,000/catheter) limits its use to the private sector.  
 
The next step to elucidate a potential anti-fibrillatory effect might be to ascertain the 
incidence of new-onset AF in the original SYMPLICITY HTN-3 population. Similarly, one could 
also look at our secondary endpoints of myocardial infarction and cardiovascular death. 





Similar confounders in Symplicity HTN-3 may have influenced the blood pressure results of 
this study. Patients who are significantly hypertensive on at least three antihypertensive 
drugs are usually shown to be non-adherent to some extent.  In this regard, drug adherence 
was not formally assessed. 
 
 In regard to the secondary endpoints, namely measurements of autonomic tone, the small 
sample size is diluted further by patients who did not return for the peak testing. 
Accordingly, it could not be clearly demonstrated that RD treatment is associated with 
restoration of autonomic imbalance. Larger randomised studies that focus on the time and 
frequency domain analysis of heart rate variability should test this hypothesis. 
 
LV mass differences may have influenced the primary endpoint outcomes, but these 
differences showed only a statistical trend at baseline. Adjusted risk ratios may help to reduce 
this possible confounder. Importantly, left atrial size, which is a better predictor of AF than 
LVH, did not differ between groups at baseline. 
 
Rare safety events may not have been detected. Blinding of the study subjects was not 
formally assessed but may be less relevant, as the primary endpoint was patient-
independent.  
 
Finally, it is not known how long the anti-fibrillatory effect will last since renal sympathetic 
nerve regrowth remains a possibility. Follow-up of patients in this study continues although 





The current study shows that renal denervation prevents subclinical atrial fibrillation and 
reduces fast atrial fibrillation incidence in patients with hypertensive heart disease. These 
salutary effects of the RD on atrial fibrillation are unique observations which have not been 
appreciated previously.  
 
Similar to Symplicity HTN-3, superior blood pressure lowering with renal denervation 
compared to a sham procedure could not be demonstrated. Although similar confounders 
may have influenced the blood pressure results the exact mechanism(s) by which renal 
denervation reduces atrial fibrillation in patients with hypertensive heart disease may, 
therefore, occur independently of blood pressure lowering.  
  
Although heart rate profiles at rest, during ambulation and after exercise improved non-
significantly with RD, the study could not demonstrate restoration of autonomic imbalance.  
RD treatment was associated with a reduced NSTEMI incidence and reduced cardiovascular 
death in patients with HHD. More extensive multi-centre prospective trials should test these 
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